TLT.v Message Board - Msg: 32438042

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TLT.v

TLT.V 0.155

-3.1%

Nov 27 2:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WalterWhite who wrote (1440)	11/28/2019 12:35:09 PM
From: ogi	Read Replies (1) of 1868

Frankly I am sorry to say that ATE management has disappointed me badly as well. Today the second announcement that trial enrollment is delayed again. This week represented almost 2 months late already and we find out that they have only enrolled 70% of the patients so far. That from a CEO who stated in Dec 18 / 2018: ""Dan Legault, chief executive officer of Antibe, commented: "The exercising of these warrants shows continued confidence by our investors in Antibe's drug development programs. Furthermore, the gross proceeds together with cash on hand fund the balance of our upcoming phase 2B clinical trial for ATB-346, expected to start in the first quarter of 2019 with results anticipated in the second quarter of 2019." That B.S from Dan was followed by 2 Private placements and now it seems the study completion will take 8 months instead of the 3 months our CEO was planning. So, not as bad as TLT but really bad. Misjudging time lines and pissing away money is a multi year history with ATE. ATE has many weeks ahead of it for the price to weaken and fill some gaps.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next